NOTCH3 Protein

NOTCH3 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NOTCH3 (Notch Receptor 3)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[NOTCH3](/genes/notch3)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9UM47" target="_blank">Q9UM47</a></td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Notch 3</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>270 kDa (full-length)</td>
</tr>
<tr>
<td class="label">Length</td>
<td>2,321 amino acids</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Plasma membrane, Endoplasmic reticulum</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Vascular smooth muscle cells, Pericytes, some neurons</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[CADASIL](/diseases/cadasil), [Vascular Dementia](/diseases/vascular-dementia), [Alzheimer's Disease](/diseases/alzheimers-disease)</td>
</tr>
</table>

NOTCH3 Protein

Overview

NOTCH3 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NOTCH3 (Notch Receptor 3)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[NOTCH3](/genes/notch3)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9UM47" target="_blank">Q9UM47</a></td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Notch 3</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>270 kDa (full-length)</td>
</tr>
<tr>
<td class="label">Length</td>
<td>2,321 amino acids</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Plasma membrane, Endoplasmic reticulum</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Vascular smooth muscle cells, Pericytes, some neurons</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[CADASIL](/diseases/cadasil), [Vascular Dementia](/diseases/vascular-dementia), [Alzheimer's Disease](/diseases/alzheimers-disease)</td>
</tr>
</table>

NOTCH3 Protein

Overview

NOTCH3 is a single-pass transmembrane receptor belonging to the Notch family of signaling proteins (NOTCH1-4 in mammals). It transduces critical signals between adjacent cells through conserved ligand (Delta/Jagged)-mediated interactions, playing essential roles in cell fate determination, vascular development, and tissue homeostasis["@gridley1997"]. Unlike other Notch receptors, NOTCH3 exhibits unique expression patterns and is predominantly expressed in vascular smooth muscle cells and [pericytes](/cell-types/pericytes), where it maintains vascular integrity and function.

Mutations in NOTCH3 cause CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), the most common hereditary form of vascular dementia and the leading cause of inherited stroke in adults. This condition affects small arteries in the brain, leading to recurrent subcortical ischemic strokes, cognitive decline, and progressive disability. Beyond CADASIL, emerging research suggests that NOTCH3 may play broader roles in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@marvie2004].

Structure and Biochemistry

Primary Structure

NOTCH3 is a large type I transmembrane receptor composed of 2,321 amino acids with a molecular weight of approximately 270 kDa. The protein is organized into three major structural domains:

Extracellular Domain (NECD, amino acids 1-1,643):

• Epidermal Growth Factor-like (EGF) repeats: 34 EGF-like repeats, 6 of which are calcium-binding (cbEGF)
• LIN-12 Notch repeats (LNR): 3 LNR domains that prevent ligand-independent activation
• Multiple cysteine residues: Form disulfide bonds essential for structural stability

• Single-pass transmembrane helix
• Anchors receptor in the plasma membrane
• Site of proteolytic cleavage (S2)

• RBP-Jκ-associated module (RAM): Binds transcriptional co-activators
• Ankyrin repeats: 6 ankyrin repeats for protein-protein interactions
• Transactivation domain (TAD): Responsible for transcriptional activation
• PEST domain: Regulates protein stability

Domain Architecture

[EGF-like repeats] - [LIN-12 repeats] - [TM] - [RAM] - [Ankyrin] - [TAD] - [PEST]
1-1643 1644-1666 1667-1757 1757-1936 1936-2131 2131-2321

Post-Translational Modifications

NOTCH3 undergoes several important post-translational modifications:

• N-linked glycosylation: Extensive glycosylation in EGF repeats affects ligand binding
• O-fucosylation: Essential for Notch signaling
• Proteolytic processing: Sequential cleavages generate active fragments

Proteolytic Activation

NOTCH3 activation involves a two-step proteolytic process:

Normal Physiological Function

Expression Pattern

NOTCH3 exhibits a distinctive expression pattern:

Primary Expression:

• Vascular smooth muscle cells (highest levels)
• [Pericytes](/cell-types/pericytes) in the cerebral vasculature
• Some populations of astrocytes

• Certain neuronal populations
• Some immune cells
• Limited expression in other tissues

Vascular Function

NOTCH3 plays essential roles in vascular homeostasis:

Vascular Development:

• Essential for blood vessel formation during embryogenesis
• Regulates arterial-venous specification
• Controls vascular smooth muscle cell investment[@domenga2004]

• Maintains vascular smooth muscle cell contractility
• Regulates blood flow through vessel tone
• Supports endothelial-pericyte interactions

Notch Signaling Pathway

Canonical Notch Signaling:

Target Genes:

• Hes family (Hes1, Hes5)
• Hey family (Hey1, Hey2, HeyL)
• Cell cycle regulators
• Extracellular matrix proteins

Role in the Blood-Brain Barrier

NOTCH3 is important for blood-brain barrier (BBB) function:

• Regulates endothelial-pericyte communication
• Maintains tight junction integrity
• Controls BBB development and maintenance

Role in CADASIL

Disease Overview

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is the most common hereditary vascular dementia, affecting approximately 1 in 50,000 individuals worldwide. It is caused by dominant mutations in the NOTCH3 gene, leading to progressive degeneration of small cerebral arteries[@joutel1996].

Clinical Features:

• Migraine with aura (often earliest symptom)
• Recurrent subcortical ischemic strokes
• Progressive cognitive decline and dementia
• Mood disorders (depression, apathy)
• White matter lesions on MRI
• Subcortical hemorrhages

• Onset typically 30-50 years
• Progressive decline over 10-30 years
• Mean survival 20-30 years after onset
• Leading to severe disability and premature death

Pathogenic Mechanisms

NOTCH3 mutations cause CADASIL through several mechanisms:

1. Accumulation of NOTCH3 Extracellular Domain:

• Mutant NOTCH3 accumulates in vessel walls
• Forms granular osmiophilic deposits (GOM)
• Disrupts vascular smooth muscle cell function

• Reduced smooth muscle cell contractility
• Altered blood flow regulation
• Increased susceptibility to ischemia

• Loss of smooth muscle cells in small arteries
• Vessel wall thickening
• Reduced vascular reserve capacity

• Impaired endothelial function
• Pericyte dysfunction
• Enhanced leukocyte infiltration[@ruchoux2003]

Mutations

Over 200 different NOTCH3 mutations have been identified in CADASIL patients:

| Mutation Type | Percentage | Common Examples |
|--------------|------------|-----------------|
| Missense (cysteine) | ~70% | R587C, C183R, C428S |
| Missense (non-cysteine) | ~15% | R90K, P496L |
| Splice site | ~10% | IVS19-2A>G |
| Small deletions | ~5% | Various |

Cysteine mutations in EGF-like repeats are most common, disrupting disulfide bond formation and protein folding.

Pathology

Key Pathological Features:

Role in Alzheimer's Disease

Interactions with AD Pathology

NOTCH3 may influence [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis through several mechanisms:

Amyloid Processing:

• γ-secretase processes both NOTCH and APP
• Competition for γ-secretase may affect Aβ production
• NOTCH signaling affects APP gene expression[@shi2020]

• NOTCH3 dysfunction affects cerebral vasculature
• May contribute to cerebral amyloid angiopathy (CAA)
• Vascular dysfunction as a risk factor for AD

Genetic Associations

• NOTCH3 variants may modify AD risk
• Some polymorphisms associated with earlier onset
• Interaction with other AD risk genes

Role in Parkinson's Disease

Emerging Evidence

Recent studies suggest potential roles for NOTCH3 in [Parkinson's disease](/diseases/parkinsons-disease):

Expression Changes:

• Altered NOTCH3 expression in PD brains
• Potential involvement in nigral neuron maintenance
• May affect glial cell function

• NOTCH3 signaling in microglia
• Potential modulation of neuroinflammatory responses
• Interaction with Parkinsonian pathology[@halliday2016]

Therapeutic Strategies

Current Approaches

| Strategy | Status | Description |
|----------|--------|-------------|
| γ-secretase inhibitors | Not beneficial | Block NOTCH cleavage but cause side effects |
| Notch modulators | Research | Agonists/antagonists of downstream signaling |
| Anti-NOTCH3 antibodies | Preclinical | Target mutant protein for clearance |
| Gene therapy | Future | Correct mutations or provide wild-type |

Emerging Therapies

1. Antibody-Based Approaches:

• Monoclonal antibodies targeting NOTCH3 extracellular domain
• Enhanced clearance of mutant protein
• Prevention of toxic accumulation

• γ-secretase modulators (GSM) that preferentially affect APP
• NOTCH-sparing GSMs in development

• Strategies to improve cerebral blood flow
• Endothelial function enhancers
• Pericyte-stabilizing compounds

CADASIL-Specific Approaches

Sarafan:

• Investigational drug for CADASIL
• Targets NOTCH3 signaling
• Currently in preclinical/early clinical development

• Antiplatelet agents for stroke prevention
• Blood pressure control
• Cognitive enhancers
• Management of migraine

Animal Models

Mouse Models

Notch3 knockout mice:

• Viable but with vascular defects
• Impaired vascular smooth muscle cell function
• Useful for studying NOTCH3 function

• Transgenic mice expressing mutant NOTCH3
• Recapitulate key pathological features
• GOM formation, smooth muscle degeneration
• Useful for therapeutic testing

Other Models

• Zebrafish: Notch3 in vascular development
• Drosophila: Evolutionary conserved functions

Biomarkers

Genetic Testing

• NOTCH3 sequencing for CADASIL diagnosis
• Identification of family-specific mutations
• Predictive testing for at-risk individuals

Clinical Biomarkers

• MRI: White matter hyperintensities, lacunar infarcts
• Magnetic resonance angiography (MRA): Vessel wall imaging
• CSF markers: May reflect disease activity

Emerging Biomarkers

• NOTCH3 extracellular domain in CSF
• Vessel-derived biomarkers
• Imaging of GOM deposits

Cross-References

• [NOTCH3 Gene](/genes/notch3)
• [CADASIL](/diseases/cadasil)
• [Vascular Dementia](/diseases/vascular-dementia)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [Vascular Smooth Muscle Cells](/cell-types/vascular-smooth-muscle-cells)
• [Pericytes](/cell-types/pericytes)

Key Publications

External Links

• UniProt: [Q9UM47](https://www.uniprot.org/uniprot/Q9UM47)
• AlphaFold: [NOTCH3](https://alphafold.ebi.ac.uk/entry/Q9UM47)
• NCBI Gene: [NOTCH3](https://www.ncbi.nlm.nih.gov/gene/4854)
• OMIM: [600276](https://www.omim.org/entry/600276)
• GeneCards: [NOTCH3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=NOTCH3)
• CADASIL Foundation: [Information and resources](https://www.cadasil.org/)

References

[@gridley1997]: Gridley, T. [Notch genes in vertebrate development](https://pubmed.ncbi.nlm.nih.gov/9275203/). Cell. 1997.

[@kopan2004]: Kopan, R. et al. [Notch signaling](https://pubmed.ncbi.nlm.nih.gov/15469841/). Cell. 2004.

[@domenga2004]: Domenga, V. et al. [Notch3 is required for vascular development](https://pubmed.ncbi.nlm.nih.gov/15286739/). Development. 2004.

[@joutel1996]: Joutel, A. et al. [CADASIL: Notch3 mutations](https://pubmed.ncbi.nlm.nih.gov/8852660/). Nature. 1996.

[@marvie2004]: Marvie, P. et al. [Notch3 and Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/12646242/). Neurobiology of Aging. 2004.

[@ruchoux2003]: Ruchoux MM, et al. [The vascular wall in CADASIL](https://pubmed.ncbi.nlm.nih.gov/14503660/). Acta Neurol Belg. 2003.

[@halliday2016]: Halliday G, et al. [NOTCH3 in Parkinson disease](https://pubmed.ncbi.nlm.nih.gov/27221046/). Acta Neuropathol. 2016.

[@shi2020]: Shi F, et al. [Notch3 and amyloid processing in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/31754920/). Mol Neurobiol. 2020.

See Also

• [Gap Analysis & Research Strategy](/wiki/gaps-gap-analysis) — activates
• [Riluzole ALS Trials](/wiki/clinical-trials-riluzole-als) — activates
• [Riluzole ALS Trials](/wiki/clinical-trials-riluzole-als) — associated_with
• [Riluzole ALS Trials](/wiki/clinical-trials-riluzole-als) — contributes_to

Pathway Diagram

The following diagram shows the key molecular relationships involving NOTCH3 Protein discovered through SciDEX knowledge graph analysis: